There is increasing evidence that monoclonal proteins are implicated in the development of peripheral neuropathy. Approximately ten percent of patients with peripheral neuropathy of unknown cause have a monoclonal protein and this rate is significantly higher than prevalence rates of monoclonal protein in comparable segments of the general population. Extensive clinical, electrophysiological and immunopathological evidences indicate that peripheral neuropathy associated with monoclonal protein are heterogeneous, including: 1. the demyelinating, predominantly sensory neuropathies associated with anti-MAG antibodies; 2. the axonal, sensory neuropathies associated with anti-sulfatide and anti-chondroitin sulfate antibodies; 3. the motor neuropathies associated with anti-GM1 antibodies. Patients with chronic polyneuropathies should be evaluated for underlying plasma cell dyscrasia.
Neuropathies associated with monoclonal gammapathies / R. Nemni, E. Gerosa, G. Piccolo, G. Merlini. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 79:6(1994), pp. 557-66-566.
|Titolo:||Neuropathies associated with monoclonal gammapathies|
NEMNI, RAFFAELLO (Primo)
|Parole Chiave:||Prednisone; Demyelinating Diseases; Combined Modality Therapy; Humans; Aged; Paraproteinemias; Immunosuppressive Agents; Nerve Tissue Proteins; Autoantigens; Paraproteins; Autoantibodies; Peripheral Nervous System Diseases; Adult; Carbohydrate Sequence; Molecular Sequence Data; Middle Aged; Plasmapheresis; Motor Neuron Disease; Female; Male|
|Settore Scientifico Disciplinare:||Settore MED/26 - Neurologia|
Settore MED/04 - Patologia Generale
Settore MED/15 - Malattie del Sangue
|Data di pubblicazione:||1994|
|Appare nelle tipologie:||01 - Articolo su periodico|